Tesamorelin is a synthetic stabilized analogue of human growth hormone-releasing hormone (GHRH). It is structurally modified at the N-terminus to enhance resistance against enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), which greatly improves its stability and bioavailability in research models compared to native GHRH. The primary biological function of Tesamorelin is to bind to GHRH receptors on pituitary somatotroph cells, stimulating the pulsatile secretion of endogenous growth hormone and subsequently elevating IGF?1 levels. It is widely applied in preclinical research focusing on pituitary function, body composition regulation, visceral fat metabolism, connective tissue repair and endocrine homeostasis. Unlike exogenous GH, Tesamorelin works through the body’s natural regulatory axis, supporting physiological, pulsatile GH release rather than sustained supraphysiological exposure. Related research also investigates its effects on lipid profile, interstitial fluid clearance and inflammatory signalling in adipose tissue. This peptide is produced via Fmoc solid-phase peptide synthesis. Each batch is subjected to rigorous quality control workflows, including HPLC purity testing, mass spectrometry identity confirmation, endotoxin detection and residual solvent screening to maintain consistent quality across batches. The lyophilized powder format protects the peptide chain from hydrolysis and oxidative damage during transit and long-term cold storage. Researchers frequently use Tesamorelin alone or in combination with other research peptides to explore synergistic effects on tissue remodelling and metabolic regulation. This product is offered exclusively for laboratory assays, animal model studies and formulation research.